The Vanguard Group, Inc. has recently announced that it has increased stake in PTC Therapeutics Inc. (NASDAQ:PTCT) by 3.40%. After grabbing 7.41 million shares, the institutional investor is now in possession of 0.24 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 10.04% having worth around $408.78 million. Moreover, RTW Investments LP increased its share by 1.48 million to have a control over 7.09 million shares. And Janus Henderson Investors US LLC raised its holdings to 1.15 million shares by acquiring 3.17 million shares or 4.29% of the stake.
PTC Therapeutics Inc. (PTCT) concluded trading on 05/25/23 at a closing price of $43.46, with 1.67 million shares of worth about $72.62 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 8.38% during that period and on Thursday the price saw a loss of about -7.43%. Currently the company’s common shares owned by public are about 73.73M shares, out of which, 70.11M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 16 analysts are covering the PTCT stock and their offered price forecasts bring an average price target of $54.20. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $75.00 and could fall to a lowest price of $35.00. The stock’s current price level is 21.69% above of average price target set by the analysts, while a rise to estimated low would result in loss of -24.17% for the stock. However, touching the estimated high of $75.00 would mean a gain of 42.05% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 102 times over the past 12 months. They bought 379,623 shares in 35 of the transactions. In 67 selling transactions, insiders dumped 164,128 shares.
Vanguard Total Stock Market ETF, Vanguard Small Cap Index Fund, and iShares Russell 2000 ETF are the top 3 mutual funds which are holding stakes in PTC Therapeutics Inc. Vanguard Total Stock Market ETF is currently holding 2.31 million shares of worth totaling $127.61 million. The company recently came buying 1167.0 shares which brought its stake up to 3.14% of the company’s outstanding shares. Vanguard Small Cap Index Fund sold 474.0 shares, after which its hold over company’s outstanding shares shrunk to 2.62%, leaving 1.93 million shares with the mutual fund that have a worth of about $106.5 million. iShares Russell 2000 ETF, after selling 1.49 million shares, have now control over 2.01% of the stake in the company. It holds 21760.0 shares of worth $81.98 million.
PTC Therapeutics Inc. (NASDAQ: PTCT) started trading at $46.76, below -$0.19 from concluding price of the previous day. However, the stock later moved at a day high price of 46.76, or with a loss of -7.43%. Stock saw a price change of -25.24% in past 5 days and over the past one month there was a price change of -16.81%. Year-to-date (YTD), PTCT shares are showing a performance of 13.86% which increased to 38.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $25.01 but also hit the highest price of $59.84 during that period. The average intraday trading volume for PTC Therapeutics Inc. shares is 858.23K. The stock is currently trading -21.81% below its 20-day simple moving average (SMA20), while that difference is down -15.85% for SMA50 and it goes to -7.40% lower than SMA200.
The Vanguard Group, Inc. acquired 7.41 million shares of PTC Therapeutics Inc. having value of about $408.78 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.24 million shares in the company valued at close to $10600589.36, or have control over 3.40% stake in the company. PTC Therapeutics Inc. (NASDAQ: PTCT) currently have 73.73M outstanding shares and institutions hold larger chunk of about 106.45% of that. Holding of mutual funds in the company is about 48.39% while other institutional holders and individual stake holders have control over 56.36% and 12.31% of the stake respectively.
The stock has a current market capitalization of $3.21B and its 3Y-monthly beta is at 0.41. It has posted earnings per share of -$7.89 in the same period. It has Quick Ratio of 1.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PTCT, volatility over the week remained 6.49% while standing at 4.35% over the month.
Analysts are in expectations that PTC Therapeutics Inc. (PTCT) stock would likely to be making an EPS of -$1.57 in the current quarter, while forecast for next quarter EPS is -$1.09 and it is -$3.06 for next year. For the current quarter EPS, analysts have given the company a lowest target -$3.04 which is -$0.58 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$2.13 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -4.80% while it is estimated to increase by 22.10% in next year. EPS is likely to grow at an annualized rate of -9.51% for next 5-years, compared to annual growth of -31.10% made by the stock over the past 5-years.
Analysts at 16 brokerage firms have issued recommendations for the PTC Therapeutics Inc. (PTCT)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.50. Out of those 16 Wall Street analysts, 6 recommended a “Buy” rating, while 7 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
Leave a Reply